Hospital

CD4+ tissue-resident memory T cells may trigger severe, and potentially fatal, asthma attacks in men aged 40 years and older.

Changes in gene expression could ultimately boost the production of inflammatory cytokines.

With the organism’s potential to cause severe symptoms, severe disease, and possible death, it is essential to care for infected individuals promptly and safely.

It's key for clinicians to optimize therapy prior to systemic agents.

More individuals who used e-cigarettes have reported pulmonary diseases compared with those who never smoked, including asthma.

Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.

AI may help to significantly speed up drug discovery and development, and help researchers end the treatment-resistant infection crisis before it’s too late.

With precision medicine, patients undergoing treatment are living longer without disease recurrence or progression and with fewer adverse effects, resulting in preservation of quality of life.

Infants younger than 6 months old are the highest risk for severe RSV infection, so researchers aim to target this group for prevention methods

AI is expected to significantly quicken the pace of drug design and development, while improving the success rate of new medicines.

This comprehensive approach is what all stakeholders, especially patients and families, need and deserve from their health care system.

The need for additional data on safety and efficacy of medicines both new and old that assess all potential risk factors is ever present, with health system pharmacists at the front lines.

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

Children with a score of higher than 30 on the CHALF Score scale will need an emergency transplant.

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.

Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.

Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.

Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.

Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.

Pneumococcal serotype 3 was prevalent regardless of vaccination status, with the most common cases being in those with chronic lung disease.

Nephrotoxic care can be improved with better risk score assessment and provider education.

Oldest adults should be prioritized for vaccinations as they remain high risk for severe conditions if infected.

Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.

In most patients who are pregnant or may become pregnant, warfarin is contraindicated due to increased risk of adverse fetal outcomes.

Coca notes the importance of precision medicine in CKD risk assessment and describes the potential impact multiple therapies can have on future CKD prediction and treatment in the future.

The principal investigator of the Centre for Cardiovascular Science at the University of Edinburgh notes that enhancing endogenous repair can lead to a breakthrough in AKI treatment.

The increased costs for patients with recurrent hyperkalemia were driven by the increased inpatient medical cost of additional time spent in the hospital following recurrence.